Pemetrexed, Pemfexy, Alimta, Armisarte, Pemetrexed Actavis (pemetrexed) is a small molecule pharmaceutical. Pemetrexed was first approved as Pemetrexed on 2004-09-20. It is used to treat mesothelial neoplasms and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat mesothelioma and non-small-cell lung carcinoma. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target thymidylate synthase, proton-coupled folate transporter, and trifunctional purine biosynthetic protein adenosine-3. Alimta's patents are valid until 2035-10-28 (FDA).
|Trade Name||Alimta, Armisarte, Pemetrexed Actavis|
|Indication||mesothelial neoplasms, mesothelioma, non-small-cell lung carcinoma|
|Drug Class||Antineoplastic thymidylate synthetase inhibitors|